Insmed Incorporated's price target raised to $119, positive Phase 2 results for pulmonary vascular resistance.

From Yahoo Finance: 2025-06-17 11:23:00

Insmed Incorporated (NASDAQ: INSM) is highlighted as one of the 10 Hot Large Cap Stocks to Buy Now. Analyst Tiago Fauth from Wells Fargo maintained a Buy rating on INSM, increasing the price target to $119. Positive Phase 2 results from the TPIP program showed a significant decrease in pulmonary vascular resistance (PVR).

The TPIP program by Insmed (INSM) has exceeded expectations, showing potential to lead in inhaled prostacyclin therapy. With a favorable safety profile and ease of dosing, it stands out in treating pulmonary arterial hypertension (PAH). Analysts see solid market potential and a positive outlook for the therapy.

Despite the potential of INSM as an investment, some believe that certain AI stocks offer greater upside potential with less downside risk. For those interested in an undervalued AI stock benefiting from Trump-era tariffs and the onshoring trend, a free report on the best short-term AI stock is available. No disclosures made in the report.



Read more at Yahoo Finance: Wells Fargo Lifts Price Target on Insmed Incorporated (INSM) to $119 From $107